Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis

Thorsten Derlin, Haefaa Alchalby, Peter Bannas, Azien Laqmani, Francis Ayuk, Ioanna Triviai, Hans Heinrich Kreipe, Frank M. Bengel, Nicolaus Kröger

Research output: Contribution to journalArticle

Abstract

Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.

Original languageEnglish (US)
Pages (from-to)1556-1559
Number of pages4
JournalJournal of Nuclear Medicine
Volume57
Issue number10
DOIs
StatePublished - Oct 1 2016
Externally publishedYes

Fingerprint

Primary Myelofibrosis
Fluorodeoxyglucose F18
Stem Cell Transplantation
Spleen
Confidence Intervals
Bone Marrow
Bone Marrow Diseases
Therapeutics
Biopsy

Keywords

  • F-FDG PET/CT
  • Allogeneic
  • Myelofibrosis
  • Positron emission tomography
  • Stem cell transplantation

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Derlin, T., Alchalby, H., Bannas, P., Laqmani, A., Ayuk, F., Triviai, I., ... Kröger, N. (2016). Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis. Journal of Nuclear Medicine, 57(10), 1556-1559. https://doi.org/10.2967/jnumed.115.166348

Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis. / Derlin, Thorsten; Alchalby, Haefaa; Bannas, Peter; Laqmani, Azien; Ayuk, Francis; Triviai, Ioanna; Kreipe, Hans Heinrich; Bengel, Frank M.; Kröger, Nicolaus.

In: Journal of Nuclear Medicine, Vol. 57, No. 10, 01.10.2016, p. 1556-1559.

Research output: Contribution to journalArticle

Derlin, T, Alchalby, H, Bannas, P, Laqmani, A, Ayuk, F, Triviai, I, Kreipe, HH, Bengel, FM & Kröger, N 2016, 'Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis', Journal of Nuclear Medicine, vol. 57, no. 10, pp. 1556-1559. https://doi.org/10.2967/jnumed.115.166348
Derlin, Thorsten ; Alchalby, Haefaa ; Bannas, Peter ; Laqmani, Azien ; Ayuk, Francis ; Triviai, Ioanna ; Kreipe, Hans Heinrich ; Bengel, Frank M. ; Kröger, Nicolaus. / Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis. In: Journal of Nuclear Medicine. 2016 ; Vol. 57, No. 10. pp. 1556-1559.
@article{26204a9d46564498a159209f60bb6978,
title = "Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis",
abstract = "Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95{\%} confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95{\%} CI, 0.36-1.0), a negative predictive value of 1.0 (95{\%} CI, 0.48-1.0), and a positive predictive value of 0.86 (95{\%} CI, 0.42-1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.",
keywords = "F-FDG PET/CT, Allogeneic, Myelofibrosis, Positron emission tomography, Stem cell transplantation",
author = "Thorsten Derlin and Haefaa Alchalby and Peter Bannas and Azien Laqmani and Francis Ayuk and Ioanna Triviai and Kreipe, {Hans Heinrich} and Bengel, {Frank M.} and Nicolaus Kr{\"o}ger",
year = "2016",
month = "10",
day = "1",
doi = "10.2967/jnumed.115.166348",
language = "English (US)",
volume = "57",
pages = "1556--1559",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "10",

}

TY - JOUR

T1 - Serial 18F-FDG PET for monitoring treatment response after allogeneic stem cell transplantation for myelofibrosis

AU - Derlin, Thorsten

AU - Alchalby, Haefaa

AU - Bannas, Peter

AU - Laqmani, Azien

AU - Ayuk, Francis

AU - Triviai, Ioanna

AU - Kreipe, Hans Heinrich

AU - Bengel, Frank M.

AU - Kröger, Nicolaus

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.

AB - Our objective was to assess the feasibility of 18F-FDG PET/CT for noninvasive monitoring of treatment response after allogeneic stem cell transplantation (SCT) for myelofibrosis. Methods: Twelve patients with myelofibrosis underwent 18F-FDG PET/CT before and after SCT. Bone marrow uptake, spleen uptake, and spleen size were assessed before and after SCT and compared with hematologic response criteria and bone marrow biopsies. Results: All patients who did not achieve complete remission remained PET-positive (P = 0.02). Extent of disease, bone marrow metabolism, spleen metabolism, and spleen volume decreased significantly in patients with complete remission (P = 0.03). PET/CT after SCT had a sensitivity of 1.0 (95% confidence interval [CI], 0.54-1.0), a specificity of 0.83 (95% CI, 0.36-1.0), a negative predictive value of 1.0 (95% CI, 0.48-1.0), and a positive predictive value of 0.86 (95% CI, 0.42-1.0) for diagnosis of residual disease. Conclusion: 18F-FDG PET/CT is feasible for noninvasive monitoring of treatment response after allogeneic SCT for myelofibrosis.

KW - F-FDG PET/CT

KW - Allogeneic

KW - Myelofibrosis

KW - Positron emission tomography

KW - Stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=84991396411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991396411&partnerID=8YFLogxK

U2 - 10.2967/jnumed.115.166348

DO - 10.2967/jnumed.115.166348

M3 - Article

VL - 57

SP - 1556

EP - 1559

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 10

ER -